- VIVUS Announces Operational Update
- VIVUS Reports Fourth Quarter and Year-End 2014 Financial Results
- VIVUS to Present at Upcoming Investor Conference
- VIVUS Announces Date of Fourth Quarter and Year End 2014 Update and Financial Results Conference Call
- VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity
Latest EventsThere are currently no upcoming events
A Growing Pipeline
VIVUS is developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health.